Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.7% – Here’s What Happened

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares were down 6.7% on Tuesday . The stock traded as low as $34.92 and last traded at $34.9410. Approximately 1,337,176 shares changed hands during mid-day trading, an increase of 45% from the average daily volume of 923,250 shares. The stock had previously closed at $37.44.

Analyst Ratings Changes

A number of equities analysts have weighed in on GPCR shares. Guggenheim dropped their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. HC Wainwright lowered their target price on Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Wednesday, October 8th. Lifesci Capital upgraded Structure Therapeutics to a “strong-buy” rating in a report on Monday, September 8th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $68.67.

Structure Therapeutics Price Performance

The business has a 50 day moving average of $28.17 and a 200 day moving average of $23.40. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of -28.44 and a beta of -1.64.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). As a group, equities analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds have recently bought and sold shares of the company. State of Wyoming bought a new position in shares of Structure Therapeutics during the second quarter worth $28,000. EverSource Wealth Advisors LLC lifted its holdings in Structure Therapeutics by 530.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after acquiring an additional 901 shares in the last quarter. National Bank of Canada FI lifted its holdings in Structure Therapeutics by 1,448.2% during the first quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock worth $51,000 after acquiring an additional 2,766 shares in the last quarter. Assetmark Inc. grew its stake in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after acquiring an additional 820 shares during the period. Finally, ANTIPODES PARTNERS Ltd increased its holdings in shares of Structure Therapeutics by 310.7% in the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company’s stock worth $74,000 after acquiring an additional 3,213 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.